Leadership shakeup at InMode (Nasdaq: INMD) brings new chairman and CFO

Rhea-AI Filing Summary

InMode Ltd. reported significant leadership changes, appointing Dr. Shlomo Nass as Chairman of the Board and director, and Moshe (Moshik) Itzkovich as Chief Financial Officer, both effective May 19, 2026. Dr. Nass, an independent director and recognized audit committee financial expert, will also chair the Audit & Investment Committee and serve on the Compensation, Nominating and Corporate Governance Committee.

Itzkovich has held senior finance roles at InMode in North America and Europe and will receive an annual base salary of CAD 500,000 with a potential quarterly discretionary bonus of up to 10% of his annual base salary. Outgoing CFO Yair Malca will remain as a consultant through the annual general meeting to support a smooth transition.

Insights

Corporate governance analyst

InMode refreshes board leadership and finance function with experienced internal and external talent.

The company appointed Dr. Shlomo Nass as Chairman and Class II director, replacing retired chairman Dr. Michael Anghel. Nass is classified as an independent director, chairs the Audit & Investment Committee, and is deemed an audit committee financial expert under SEC and Nasdaq rules.

Moshik Itzkovich was promoted to CFO after serving as Senior Vice President of Finance for North America and Europe, providing continuity in the finance function. Former CFO Yair Malca stays on as consultant through the annual general meeting, which supports an orderly handover. The filing focuses on governance and leadership rather than financial performance.

Key Figures

Effective date of appointments: May 19, 2026 Age of Dr. Nass: 66 years Age of Mr. Itzkovich: 41 years +3 more

6 metrics

Effective date of appointments May 19, 2026 Date Dr. Nass and Mr. Itzkovich assumed new roles

Age of Dr. Nass 66 years Age of new Chairman and director

Age of Mr. Itzkovich 41 years Age of new Chief Financial Officer

CFO base salary CAD 500,000 per year Annual base salary for new CFO Itzkovich

CFO bonus opportunity Up to 10% of annual base salary Maximum quarterly discretionary bonus for CFO

Class II director term Until 2027 annual general meeting Term of office for Dr. Nass as Class II director

Key Terms

independent director, audit committee financial expert, Compensation Policy, forward-looking statements, +2 more

6 terms

independent director financial

"Dr. Nass is an independent director as defined by Nasdaq listing standards."

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

audit committee financial expert financial

"The Board has determined that Dr. Nass is an “audit committee financial expert” as defined under the rules of the Securities and Exchange Commission"

A person on a company’s board who has deep knowledge of accounting, financial reporting and auditing, able to understand and question the books, controls and audit work like a trained mechanic inspecting an engine. Investors care because that expertise helps spot errors, weaknesses or misleading statements early, improving the likelihood that financial reports are accurate and reducing the risk of surprises that can hurt a company’s value.

Compensation Policy financial

"compensation the Company offers its other non-employee directors, in accordance with the Company’s Compensation Policy"

forward-looking statements regulatory

"The information in this press release includes forward-looking statements within the meaning of the federal securities laws."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

director and officer liability insurance financial

"to be an insured under the Company’s director and officer liability insurance policy"

related party transactions financial

"there have been no related party transactions between the Company and Dr. Nass that would be reportable under Item 404(a) of Regulation S-K."

Transactions between a company and people or entities that have close ties to it—such as executives, board members, major shareholders, family members, or related companies—where the parties are not independent. These deals matter to investors because they can create conflicts of interest or hide favorable terms that distort a company’s true profits and risks; think of it like a business buying or selling to a family member instead of using the open market, which can lead to biased prices or undisclosed obligations.

Form 6-K: How Foreign Companies Report to the SEC →

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

INMODE LTD.

(Exact name of registrant as specified in its charter)

Tavor Building, Sha’ar Yokneam

P.O. Box 533

Yokneam 2069206 Israel

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes ☐ No ☒

Appointment of New Director

On May 19, 2026, the Board of Directors (the “Board”) of InMode Ltd. (the “Company”) appointed Dr. Shlomo Nass to the Board, effective immediately. He fills the vacancy left by the previously announced departure of Dr. Michael Anghel on May 5, 2026.

Dr. Nass will serve as a Class II Director, holding office until the annual general meeting of shareholders to be held in 2027. Dr. Nass is an independent director as defined by Nasdaq listing standards. Dr. Nass will serve as Chairman of the Board, as Chairman of the Board’s Audit & Investment Committee and as a member of the Board’s Compensation, Nominating and Corporate Governance Committee. The Board has determined that Dr. Nass is an “audit committee financial expert” as defined under the rules of the Securities and Exchange Commission and that he meets the financial sophistication requirements under applicable Nasdaq Listing Rules.

Dr. Nass, age 66, currently serves as a senior partner at Firon, an Israeli law firm. He is a member of the Israeli Bar Association and is a Certified Public Accountant in Israel. Dr. Nass is also a Certified Information System Auditor, C.I.S.A (USA). Dr. Nass is a lecturer on Corporate Law at Bar-Ilan University and in the Directors’ Training seminar at “Lahav” Executive Education at the Recanati Faculty of Management in Tel-Aviv University.

Dr. Nass will be entitled to the compensation the Company offers its other non-employee directors, in accordance with the Company’s Compensation Policy, as in effect from time to time, including annual retainers and equity compensation. Dr. Nass is entitled to indemnification and exculpation and to be an insured under the Company’s director and officer liability insurance policy, as are the Company’s other executive officers and directors. There is no arrangement or understanding between Dr. Nass and any other person pursuant to which he was appointed as a director. Since the beginning of the last fiscal year of the Company, there have been no related party transactions between the Company and Dr. Nass that would be reportable under Item 404(a) of Regulation S-K.

Appointment of New Chief Financial Officer

On May 20, 2026, the Company announced the appointment of Moshe (Moshik) Itzkovich as the Company’s new Chief Financial Officer, effective May 19, 2026. As previously disclosed, the Company’s prior Chief Financial Officer, Yair Malca, remains engaged as a consultant to ensure a smooth transition.

Mr. Itzkovich, age 41, previously served as the Company’s Senior Vice President, Finance, for North America and Europe since January 2026. Prior to that, Mr. Itzkovich served the Company and certain of its wholly owned subsidiaries in various roles, including as Vice President of Finance, North America from January 2022 to December 2025. From August 2018 to December 2021, Mr. Itzkovich served as the Vice President of Finance of Home Skinovations Ltd. Mr. Itzkovich is also a member of the board of directors of the Company’s Canadian subsidiary, Invasix Corp. Mr. Itzkovich holds a degree in Accounting and Economics from Tel Aviv University.

Mr. Itzkovich will receive an annual base salary of CAD 500,000 and is entitled to a quarterly discretionary bonus of up to 10% of his annual base salary.

Mr. Itzkovich is entitled to indemnification and exculpation and to be an insured under the Company’s director and officer liability insurance policy, as are the Company’s other executive officers and directors. There is no arrangement or understanding between Mr. Itzkovich and any other person pursuant to which he was appointed as the Company’s Chief Financial Officer. Since the beginning of the last fiscal year of the Company, there have been no related party transactions between the Company and Mr. Itzkovich that would be reportable under Item 404(a) of Regulation S-K.

A copy of the press release announcing the respective appointments of Dr. Nass and Mr. Itzkovich is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit No.		Description of Exhibit
99.1		Press Release dated May 20, 2026

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	InMode Ltd.
	By: /s/ Moshe Mizrahy
	Moshe Mizrahy
May 20, 2026	Chief Executive Officer

Exhibit 99.1 

 

InMode Appoints Dr. Shlomo Nass as Chairman of the Board and

Moshik Itzkovich as Chief Financial Officer

YOKNEAM, Israel, May 20, 2026 -- InMode Ltd. (Nasdaq: INMD) (“InMode” or the “Company”), a leading global provider of innovative medical technologies, today announced the appointment of Dr. Shlomo Nass as Chairman of the Company’s Board of Directors (the “Board”) and Moshik Itzkovich as Chief Financial Officer, effective immediately.

Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month, and will lead the Board in supporting the Company’s long-term strategic growth and governance priorities. Dr. Nass brings decades of expertise in corporate law, accounting, governance, and audit oversight, with extensive experience advising public and private companies on complex regulatory and financial matters.

“We are pleased to welcome Shlomo as Chairman of the Board,” said Moshe Mizrahy, Chief Executive Officer. “His deep expertise in corporate governance, financial oversight, and regulatory matters, combined with his extensive leadership experience, will be invaluable as we continue to execute our strategic priorities and drive long-term shareholder value.”

“On behalf of the Board and management team, we thank Michael Anghel for his many years of commitment and service to InMode and wish him all the best going forward,” Mizrahy concluded.

At the same time, InMode announced the appointment of Moshik Itzkovich as Chief Financial Officer. Moshik has held senior finance roles at InMode and was previously Senior Vice President of Finance. He replaces Yair Malca, who stepped down earlier this month and will serve as a consultant at least through the Company’s Annual General Meeting to ensure a smooth transition.

“Having partnered closely with Yair over the last three years, Moshik brings continuity, financial expertise, and strategic insight to this role,” said Moshe Mizrahy, Chief Executive Officer. “We are confident he is well positioned to build on our strong financial foundation and support the Company’s long-term objectives.”

“We thank Yair for his many years of exceptional service. His leadership and contributions have been instrumental to our success, and he played a key role in our transition to a publicly traded Company. He leaves InMode with a very strong balance sheet and solid operational and financial foundations in place for his successor. We are grateful for his lasting impact on the Company,” Mizrahy concluded.

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

Forward-Looking Statements

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode’s future financial or operating performance, including the actual amount of share repurchases made by the Company, if any. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would” and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2026, and our subsequent public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

Investor Relations Contact:

Miri Segal-Scharia

MS-IR LLC

ir@inmodemd.com

FAQ

What leadership changes did InMode (INMD) announce in this 6-K filing?

InMode appointed Dr. Shlomo Nass as Chairman of the Board and Class II director, and Moshe (Moshik) Itzkovich as Chief Financial Officer, both effective May 19, 2026. Former chairman Dr. Michael Anghel retired, and former CFO Yair Malca remains as a consultant.

What roles will Dr. Shlomo Nass hold at InMode (INMD)?

Dr. Nass will serve as Chairman of the Board, a Class II director, Chairman of the Audit & Investment Committee, and member of the Compensation, Nominating and Corporate Governance Committee. He is an independent director and considered an audit committee financial expert under SEC and Nasdaq rules.

Who is InMode’s new Chief Financial Officer and what is his background?

InMode’s new CFO is Moshe (Moshik) Itzkovich, previously Senior Vice President, Finance, for North America and Europe. He has held multiple finance roles within InMode and its subsidiaries, serves on the board of Invasix Corp., and holds an Accounting and Economics degree from Tel Aviv University.

What is the compensation package for InMode’s new CFO, Moshik Itzkovich?

Itzkovich will receive an annual base salary of CAD 500,000 and may earn a quarterly discretionary bonus up to 10% of his annual base salary. He is also entitled to indemnification, exculpation, and coverage under InMode’s director and officer liability insurance policy.

Is there any related party transaction disclosure for Dr. Nass or Mr. Itzkovich at InMode?

The company states that since the beginning of its last fiscal year, there have been no related party transactions with either Dr. Nass or Mr. Itzkovich that would be reportable under Item 404(a) of Regulation S-K. This suggests no disclosed conflicts of interest in their appointments.

How is continuity ensured following InMode’s CFO transition from Yair Malca to Moshik Itzkovich?

Former CFO Yair Malca will remain engaged as a consultant at least through InMode’s Annual General Meeting. This arrangement is intended to support a smooth transition as Moshik Itzkovich assumes the CFO role, leveraging their prior close working relationship in senior finance roles.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 9.5 KB